ClinicalTrials.gg
CompletedNCT06720766MASLDUpdated Oct 1, 2026

Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity

An observational study in Fatty Liver Disease, sponsored by The Third People's Hospital of Chengdu. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by The Third People's Hospital of Chengdu · Observational

Updated Oct 1, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
565
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 54 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Enrollment
29th of 53
565 · median 880
Started
2023
with 19 others
Observational
53 of 142
23 open now
Registered
118th of 142
by date

Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 29th largest by enrollment of the 53 observational ones that give a count, is one of 20 that started in 2023, is one of 53 observational ones, and was the 118th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity.

The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.

03

Conditions studied

  • Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consisted of patients aged 18 years or older who provided written informed consent and were scheduled to undergo bariatric surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 years or older who provided written
  2. Patients who schedule to undergo bariatric surgery and a liver (LB) for the investigation of suspected MASLD
  3. Patients who schedule to undergo FibroScan examination

Exclusion criteria

Exclusion Criteria:

  1. Patients with ascites or pregnant women
  2. Patients with any active implantable medical device (such as a pacemaker or defibrillator)
  3. Patients who have undergone liver transplantation
  4. Patients with cardiac failure and/or significant valvular disease
  5. Patients with haemochromatosis
  6. Patients who have refused to undergo LB or blood tests
  7. Patients with a confirmed diagnosis of active , or other terminal disease
  8. Patients participating in another clinical trial within the preceding 30 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
565 participants (actual)
Target follow-up
1 Month
Patient registry
Yes

Interventions

  • Diagnostic testFibbroScan and biopsy

    In individuals with obesity, a biopsy is performed within a week after undergoing an FibroScan examination.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy

    Estimated using the area under the receiver operating characteristic curves for the categories of steatosis and fibrosis

    Time frame: Through study completion, an average of 1 year

  2. Cut-off values

    Optimal thresholds for application on people with obesity

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
  • The Third People's Hospital of Chengdu
    Chengdu, Sichuan, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2025, 23 months.

Of 159 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's 23 months is below that.

Counting every sponsor, half of 170 studies reached it within 49 months; a quarter within 25 and three quarters within 124.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Mar 2025 → Sep 2025 and completion Mar 2025 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 6, 2024
StartActual
Oct 24, 2023
Primary completionActual
Sep 30, 2025was Mar 2025
CompletionActual
Jul 31, 2026was Mar 2025
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 1, 2026
Primary completion
Mar 31, 2025→Sep 30, 2025 (actual)
Oct 1, 2026
Study completion
Mar 31, 2025→Jul 31, 2026 (actual)
Oct 1, 2026
Enrollment
600 (estimated)→565 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Completed
    Primary completion Mar 31, 2025→Sep 30, 2025 (now actual)
    Study completion Mar 31, 2025→Jul 31, 2026 (now actual)
    Enrollment 600 (estimated)→565 (actual)
    + 5 other changes: verification date, responsible party, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06720766
Lead sponsor
The Third People's Hospital of Chengdu
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Oct 24, 2023
Primary completion
Sep 30, 2025
Completion
Jul 31, 2026
Last update
Oct 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion